Oren Gilad - 03 Apr 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President/CEO, Director
Signature
/s/ John P. Hamill, as Attorney-in-Fact
Issuer symbol
APRE
Transactions as of
03 Apr 2025
Net transactions value
+$10,110
Form type
4
Filing time
04 Apr 2025, 07:30:11 UTC
Previous filing
31 Mar 2025
Next filing
11 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $5,616 +3,003 +0.88% $1.87 343,123 03 Apr 2025 Direct
transaction APRE Common Stock Purchase $4,495 +2,497 +0.73% $1.80 345,620 03 Apr 2025 Direct
holding APRE Common Stock 1,200 03 Apr 2025 By Daughter F1
holding APRE Common Stock 600 03 Apr 2025 By Son F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.